Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients - SANOB Study (SANOB)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01853787
Recruitment Status : Completed
First Posted : May 15, 2013
Last Update Posted : July 10, 2015
Sponsor:
Collaborators:
Fondazione Salvatore Maugeri
Università degli Studi di Ferrara
Information provided by (Responsible Party):
Pierachille Santus, University of Milan

Brief Summary:
  • Among many other causes, Bronchial obstruction in Chronic Obstructive Pulmonary Disease (COPD) is also caused by inflammation of peripheral airways walls.
  • Neutrophils and other inflammatory mediators like Interleukin-6 (IL6), Interleukin-8 (IL8), Interleukin-1 alpha (IL-1 alpha),Interleukin-1beta (IL-1 beta), Tumor Necrosis Factor alfa (TNF-alfa), Reactive Oxygen Species (ROS), Leukotriene B4 (LTB4), Nitric Oxyde (NO) are implicated in the inflammation.
  • NO is produced in response to physical and chemical stress on bronchial epithelium and plays a critical role in small airways remodelling
  • Exhaled NO concentration is usually used to monitor bronchial inflammation
  • The relationship between stretch and strain of small airways and bronchial inflammation is not well understood.
  • The investigators hypothesis is that cyclic opening and closure of peripheral obstructed airways through the consequent stretching and strain acting on them can provoke an inflammatory response which can be monitored by exhaled NO.
  • The pharmacological effects of bronchodilators may play a role on bronchial inflammation by reducing the stretching stress on bronchiolar walls thus reducing the production of NO in exhalate
  • Data about these physiopathological aspects is missing in literature.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease (COPD) Drug: Formoterol Fumarate Drug: Salmeterol Phase 4

Detailed Description:

Bronchial inflammation in COPD represents one of the main causes of not fully reversible obstruction and airflow limitation. The main inflammatory cells involved are represented by the neutrophils, while some inflammatory mediators like Interleukin-6 (IL6), Interleukin-8 (IL8), Interleukin-1 alpha (IL1alpha), Interleukin-1 beta (IL1beta), Tumor Necrosis Factor alfa (TNFalfa), Reactive Oxygen Species (ROS), Leukotriene B4 (LTB4) and Nitric Oxide (NO) provoke the disruption of the elastic alveolar bonds that support the small airways, thus invalidating their physical and mechanical characteristics. During tidal volume respiration, in such patients, the chronically obstructed small airways are subjected, the investigators suppose, to one of the following effects:

  • a total closure of the smaller bronchioli causing atelectasis
  • a cyclic opening and closure of the airways thus provoking friction and strain stress and an inflammatory response of mechanical origin.

The Fraction of Exhaled Nitric Oxyde (FeNO) concentration is largely used in clinical practice as a marker to monitor the lung inflammatory status. Formoterol and Salmeterol are two of the most used Long Acting Beta 2 Agonists (LABA) for inhaled therapy of COPD, representing the basis of the bronchodilator therapy in this disease.

The purpose of the study is to evaluate the possible mechanical origin of the bronchial inflammation and then the capacity of inhaled LABA in acute conditions to modify the trend of production of NO by reducing stretching and strain forces. Thus the possible decline of exhaled NO concentration will be used as an index of the small airways inflammatory state occurring after inhaled therapy.

To do this the investigators will measure the exhaled NO concentration in COPD patients with moderate to severe obstruction, that is a Forced Expiratory Volume less than 70% of predicted value (FEV1<70%pred). The evaluation will be done in four different moments:

  1. at baseline, after 72 hours of pharmacological washout conditions
  2. at 30 minutes after the assumption of inhaled therapy (Salmeterol 50 mcg or Formoterol 12 mcg in double blind conditions)
  3. at 60 minutes after step 2
  4. at 180 minutes after step 2 Together with NO concentration, also the Respiratory Frequency and Tidal Volume will be registered during each evaluation.

All the subjects will be inpatients accessing a respiratory rehabilitation unit or outpatients of the ambulatory service. After every NO measure, a functional respiratory assessment will be made (spirometry, plethysmography, Carbon Monoxide (CO) diffusion lung test, Single Breath N2 washout test), together with an arterial blood gas analysis.

At every step a dyspnoea assessment will be made by Visual Analogic Scale, while Modified Medical Research Council (mMRC) scale will be assessed at the beginning of the test.

Every patient will repeat the four step assessment after 72 hours, while a double blind pharmacological crossover will be performed, thus creating a controlled study in witch every patients, at the end of the study, will take Salmeterol and Formoterol in a randomized way.

For the study duration all the patients will perform a pharmacological washout (living the short acting inhaled Beta 2 agonists as rescue medication)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 49 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: Acute Bronchodilation and Bronchial Inflammation: Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients. Stretching of Airways and Nitric Oxide in Bronchodilation, SANOB Study
Study Start Date : July 2014
Actual Primary Completion Date : June 2015
Actual Study Completion Date : June 2015


Arm Intervention/treatment
Experimental: Formoterol Fumarate
At study day n°1 the patients will be randomized to take either Salmeterol or Formoterol in a double blind way.
Drug: Formoterol Fumarate
Formoterol Fumarate, one inhalation of 12 mcg via MDI (Metered Dose Inhaler) Modulite will be taken in double blind randomized way immediately after T0 evaluation.
Other Name: Foradil spray, Novartis Farma S.p.A.

Drug: Salmeterol
Salmeterol 50 mcg via MDI (Metered Dose Inhaler), one inhalation only, immediately after T0 evaluation
Other Name: Serevent, GlaxoSmithKline S.p.A.

Active Comparator: Salmeterol
The second study arm represents the crossing over arm. Every patient, at study day number 2 will take a different medication (Salmeterol 50 mcg or Formoterol 12 mcg) from that taken at the study day n° 1.
Drug: Formoterol Fumarate
Formoterol Fumarate, one inhalation of 12 mcg via MDI (Metered Dose Inhaler) Modulite will be taken in double blind randomized way immediately after T0 evaluation.
Other Name: Foradil spray, Novartis Farma S.p.A.

Drug: Salmeterol
Salmeterol 50 mcg via MDI (Metered Dose Inhaler), one inhalation only, immediately after T0 evaluation
Other Name: Serevent, GlaxoSmithKline S.p.A.




Primary Outcome Measures :
  1. Change in exhaled Nitric Oxide concentration after Long acting Beta 2 Agonist assumption [ Time Frame: - At baseline, after 30 minutes of LABA assumption, after 60 minutes of LABA assumption, after 180 minutes of LABA assumption ]

    The evaluation of exhaled Nitric Oxide concentration will be performed following the schedule below:

    • at baseline (T0), after 72 hours of inhalatory therapy washout
    • 30 minutes (T1) after the assumption of a inhaled bronchodilator (Salmeterol 50 mcg or Formoterol 12 mcg)
    • 60 minutes after T0 (T2)
    • 180 minutes after T0 (T3) every patient will repeat the same four steps in two different days after 72 hours of pharmacological washout, crossing over in blind conditions the bronchodilator taken the previous study day.

    The measurements of Exhaled NO will be performed by Medi-Soft Exp'air FeNo concentration sampling device, Sorinnes (Dinant) Belgium. At every step, will be performed 3 measurements at different flows (50 ml/sec, 100 ml/sec, 150 ml/sec and 350 ml/sec), for a total of 12 valid measurements for each step.

    Alveolar NO and Bronchial Wall NO concentrations will be taken in consideration.



Secondary Outcome Measures :
  1. Change in static plethysmographic volumes, assessment of desufflation and resistances after Long acting Beta 2 Agonist assumption and [ Time Frame: At baseline, after 30 minutes of LABA assumption, after 60 minutes of LABA assumption, after 180 minutes of LABA assumption ]

    The evaluation of pulmonary desufflation and pulmonary specific resistances (sRAW) will be performed with a plethysmographic maneuver for each of the following steps:

    • at baseline (T0), after 72 hours of inhalatory therapy washout
    • 30 minutes (T1) after the assumption of a inhaled bronchodilator (Salmeterol 50 mcg or Formoterol 12 mcg)
    • 60 minutes after T0 (T2)
    • 180 minutes after T0 (T3) every patient will repeat the same four steps in two different days after 72 hours of pharmacological washout, crossing over in blind conditions the bronchodilator taken the previous study day.

    The considered pulmonary volumes will be the Residual Volume and the Functional Residual Capacity, while Specific Resistances of AirWays (sRAW)will be evaluated using a Jaeger (Germany) plethysmographic cabin. At every step, 3 measurements will be performed, following the American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines on pulmonary Function testing.


  2. Diffusion Lung Capacity for Carbon Monoxide (DLCO) and Alveolar Volume (VA) variation from baseline [ Time Frame: At baseline, after 30 minutes of LABA assumption, after 60 minutes of LABA assumption, after 180 minutes of LABA assumption ]

    The evaluation of DLCO and VA will be assessed performing the Single Breath method for each of the following steps:

    • at baseline (T0), after 72 hours of inhalatory therapy washout
    • 30 minutes (T1) after the assumption of a inhaled bronchodilator (Salmeterol 50 mcg or Formoterol 12 mcg)
    • 60 minutes after T0 (T2)
    • 180 minutes after T0 (T3) Every patient will repeat the same four steps in two different days after 72 hours of pharmacological washout, crossing over in blind conditions the bronchodilator taken the previous study day.

    DLCO and VA will be obtained using a Jaeger (Germany) pneumotachograph with an integrated gas analyzer, by means of a fixed gas mixture made as follows : 10% Helium, 6% Carbon Monoxide, 84% Nitrogen At every step 3 consecutive measurements will be performed, following the ATS/ERS guidelines on pulmonary Function testing.


  3. Modification of arterial gases concentration after bronchodilator therapy in acute conditions [ Time Frame: At baseline, after 180 minutes of LABA assumption ]

    An arterial blood sampling will be taken for each of the following steps:

    • at baseline (T0), after 72 hours of inhalatory therapy washout
    • 180 minutes after T0 (T3) Every patient will repeat the same two steps in two different days after 72 hours of pharmacological washout, crossing over in blind conditions the bronchodilator taken the previous study day.

    Partial arterial pressure of Oxygen and Partial arterial pressure of Carbon Dioxide will be obtained using a arterial gas analyzer GEM Premier 3000


  4. Closing Capacity variability from baseline at the Single Breath Nitrogen Washout test [ Time Frame: At baseline, after 30 minutes of LABA assumption, after 60 minutes of LABA assumption, after 180 minutes of LABA assumption ]

    The evaluation of the appearance of the CLosing Capacity (CC) will be assessed performing the Single Breath Nitrogen Washout test (SBN2 test) for each of the following steps:

    • at baseline (T0), after 72 hours of inhalatory therapy washout
    • 30 minutes (T1) after the assumption of a inhaled bronchodilator (Salmeterol 50 mcg or Formoterol 12 mcg)
    • 60 minutes after T0 (T2)
    • 180 minutes after T0 (T3) Every patient will repeat the same four steps in two different days after 72 hours of pharmacological washout, crossing over in blind conditions the bronchodilator taken the previous study day.

    The CC will be obtained using Vmax, Jaeger (Germany) pneumotachograph with an integrated gas analyzer. The parameters considered will be the phase III (alveolar phase) and the phase IV (Closing Capacity appearance) at the SBN2 test.

    At every step 3 consecutive measurements will be performed, following the ATS/ERS guidelines on pulmonary function testing.


  5. Change from baseline in dyspnoea, evaluated with VAS (Visual Analogue Scale). [ Time Frame: At baseline, after 30 minutes of LABA assumption, after 60 minutes of LABA assumption, after 180 minutes of LABA assumption ]

    The evaluation of grade of dyspnea will assessed through the VAS scale for each of the following steps:

    • at baseline (T0), after 72 hours of inhalatory therapy washout
    • 30 minutes (T1) after the assumption of a inhaled bronchodilator (Salmeterol 50 mcg or Formoterol 12 mcg)
    • 60 minutes after T0 (T2)
    • 180 minutes after T0 (T3) Every patient will repeat the same four steps in two different days after 72 hours of pharmacological washout, crossing over in blind conditions the bronchodilator taken the previous study day.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Signature of informed consent
  • COPD patients with age raging from 50 to 85 years old
  • Patients with at least a history of COPD of one year
  • COPD patients clinically stable in the last three months
  • COPD subjects with FEV1 (Forced Expiratory Volume in 1st second)<70% of predicted value
  • FEV1/FVC (Forced Expiratory Volume in 1st second/Forced Vital Capacity) <88% (males) or <89% (females) of LLN (Low Levels of Normality)
  • COPD former or active smokers with at least a smoking history of 20 pack year

Exclusion Criteria:

  • Acute Bronchial Exacerbation at recruitment
  • Fertile women with age between 18 and 50 years old or with active period
  • Pregnancy
  • Subjects enrolled in other clinical trials or that have taken part in one of them in the month preceding the enrollment.
  • FEV1/FVC more than 70% of predicted value in basal conditions
  • FEV1 more than 70% of predicted value in basal conditions
  • Known deficit of alpha 1 antitrypsin
  • Subjects that underwent a Lung Volume Reduction Surgery (LVRS)
  • Subjects with known positivity to Human Immunodeficiency Virus (HIV)
  • Misuse of alcool or drugs
  • Lack of compliance in performing respiratory tests
  • Subjects not capable to follow the study prescriptions because of psychic disorders or language problems.
  • Long Term Oxygen Therapy with flows > 6 litres per minute (l/min) at rest

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01853787


Locations
Layout table for location information
Italy
Clinica di Malattie dell'Apparato Respiratorio, Dipartimento di Scienze Mediche, Università di Ferrara
Ferrara, Italy, 44121
: Pneumologia Riabilitativa-Fondazione Maugeri-Istituto Scientifico di Milano- IRCCS
Milano, Italy, 20138
Sponsors and Collaborators
University of Milan
Fondazione Salvatore Maugeri
Università degli Studi di Ferrara
Investigators
Layout table for investigator information
Study Director: Pierachille santus, Md, PhD Università degli Studi di Milano-Pneumologia Riabilitativa-Fondazione Salvatore Maugeri-MILANO
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Pierachille Santus, Head of Pulmonary Rehabilitation Unit, University of Milan
ClinicalTrials.gov Identifier: NCT01853787    
Other Study ID Numbers: 898CEC
First Posted: May 15, 2013    Key Record Dates
Last Update Posted: July 10, 2015
Last Verified: July 2015
Keywords provided by Pierachille Santus, University of Milan:
COPD
bronchial inflammation
NO concentration
small airways
LABA
Small Airways Stretching
Stretch and strain of small airways in COPD
Acute LABA effect on NO production
Pulmonary desufflation
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Formoterol Fumarate
Salmeterol Xinafoate
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action